IL-23
![](https://pbs.twimg.com/profile_images/1194991303307747335/hZjMpBuI.jpg)
3 years 3 months ago
COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI.
#OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM
![](https://pbs.twimg.com/media/E3Bs9YSXwAMEjqV.jpg)
![](https://pbs.twimg.com/profile_images/908324013566513153/YdK61O5C.jpg)
3 years 3 months ago
2021 GRAPPA STRONG recs (cont'd):
*⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
🚫strong rec against IL17i
2021 GRAPPA CONDITIONAL recs for:
*⃣ Uveitis: TNFi (not ETN), CyA
*⃣ Crohn's Dz & UC: IL23i, JAKi, MTX
OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
![](https://pbs.twimg.com/media/E3Doc4_XIAkW9vd.jpg)
![](https://pbs.twimg.com/profile_images/908324013566513153/YdK61O5C.jpg)
3 years 3 months ago
2021 GRAPPA STRONG recs: *⃣Axial PsA/arthritis, biologic-naive or IR: TNFi, IL17i, JAKi *⃣Peripheral arthritis biologic-IR: above + IL23i *⃣Peripheral arthritis DMARD-IR: above + IL12/23i *⃣Peripheral arthritis DMARD-naive: above + PDE4i + csDMARD OP0229 #EULAR2021 @RheumNow https://t.co/Z2Nv073yoU
![](https://pbs.twimg.com/media/E3DpEI-XoAQy6Cj.jpg)
![](https://pbs.twimg.com/profile_images/1324821320429981703/dAiq_hpT.jpg)
3 years 3 months ago
Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic
⭐️ACR20, 50,70 response
⭐️significant resolution of enthesitis/dactylitis
Abs#OP0228
#EULAR2021 @RheumNow
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com
Listen by Clicking below:
1.…
![](https://pbs.twimg.com/profile_images/847812732007133184/hIbnEHt3.jpg)
3 years 3 months ago
The COSMOS study results showed that GUS 100 mg Q8W showed ⬆️ ACR20 vs PBO at W24 in TNFi IR PsA pts who had tried 1-2 prior TNFi. What MOA do you choose after 1st TNFi IR in your PsA pts? Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/Jb7GqkHtYz
The evidence-based recommendations from the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis were presented at #EULAR2021. The goal (as per 2009 recommendations) was “To develop…
![](https://pbs.twimg.com/profile_images/1194991303307747335/hZjMpBuI.jpg)
3 years 3 months ago
DISCOVER 1&2: whole blood transcriptome in PsA: dysregulation of immune cell profiles vs. Ctrl
Guselkumab modulates genes expr towards normalization of immune cell composition. Would be interesting to look at STissue
signatures too 🧐 @StefanSiebert1 #POS0195 @Rheumnow #EULAR2021 https://t.co/7WChCP3U6W
![](https://pbs.twimg.com/media/E3CLsVNXwAIcwes.jpg)